Abstract
Inflammatory Bowel Disease (IBD) comprises chronic inflammatory disorders affecting the gastrointestinal tract, such as Crohn’s Disease (CD) and Ulcerative Colitis (UC). The escalating global incidence of IBD is multifactorial, involving genetic, microbial, environmental and immunological factors. Despite current therapies emphasizing immune suppression, sustained efficacy remains elusive. Recently, Stem Cell Therapy (SCT) has emerged as a potential avenue for inducing remission in IBD patients. Intestinal Stem Cells (ISCs) have gained attention for their recent emergence in research and potential cultivation into organoids, offering a promising source for IBD treatment. This review focuses on the potential of ISC SCT, emphasizing its organoid culturing capabilities. It highlights organoids’ applications in IBD research, monitors advancements in animal and human trials and examines current limitations and future directions in organoid research for IBD treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
